|Bid||0.5510 x 4000|
|Ask||0.5700 x 1800|
|Day's range||0.5514 - 0.5900|
|52-week range||0.5500 - 4.7300|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
On today's call, Andy Kidd, our president and chief executive officer, will discuss our business and clinical development progress; then Ashish Khanna, our chief financial officer and chief business officer, will review our financial results. Please see the forward-looking statement disclaimer in our financial results release issued this afternoon and the risk factors in the company's current and subsequent filings with the SEC.
Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.
Investors need to pay close attention to Aptinyx (APTX) stock based on the movements in the options market lately.